Blaze Vector Production

Research-grade AAV is used to advance early discovery and development efforts, including proof-of-concept studies, target validation, and initial assessments of vector design and manufacturability. It provides material needed to generate preclinical data and determine whether programs are ready to move forward toward larger-scale production and clinical development.

Blaze provides fast, flexible production of research-grade AAV tailored for early-stage work. The service enables gene therapy developers to quickly obtain the material needed for proof-of-concept studies, helping evaluate therapeutic potential and make critical early decisions with confidence. Starting development with a commercially viable platform, like Blaze, can support easier development, scale-up, reduce bridging studies, and minimize risks to future approvals.

Developers typically transition from in-house lab production to a CDMO when early data show promise and larger, more consistent batches are needed for advanced studies. This move helps ensure higher-quality materials, scalable processes, and smoother progression toward preclinical or cGMP manufacturing, reducing risks as programs advance toward regulatory milestones.

While we don’t provide traditional CRO services, like preclinical or clinical trial management, we work closely with clients to support their manufacturing strategy throughout the development lifecycle and maintain preferred partnerships with CROs that we can connect our clients to as needed.